Fate Therapeutics (FATE)

Fate Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).

Download CSV

10.6M

Short interest

settlement 2026-10-15

8.7

Days to cover

+3.5 days vs prior

37.7%

Short share of volume

2026-11-02

1,977

Fails to deliver

settlement 2026-10-08

Thu 12 Nov

Next earnings

estimated date

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in FATE is 10,618,410 shares, up 1,231,959 shares over the last month. Over the last 48 readings it ranged from 6,831,984 shares (31 October 2025) to 16,374,114 shares (31 March 2025). At the reported average volume of 1.2M shares a day that is 8.7 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/fate" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	10,618,410	-1.3%	1,216,826	8.73
2026-09-30	10,759,313	+14.6%	2,041,291	5.27
2026-09-15	9,386,451	+3.0%	893,769	10.50
2026-08-31	9,111,011	+7.1%	1,462,950	6.23
2026-08-14	8,508,135	+10.8%	2,593,866	3.28
2026-07-31	7,679,112	+5.0%	1,675,422	4.58
2026-07-15	7,315,037	-1.6%	3,690,730	1.98
2026-06-30	7,432,049	-31.3%	6,076,171	1.22
2026-06-15	10,821,669	+1.2%	3,616,075	2.99
2026-05-29	10,697,112	+10.0%	5,176,029	2.07
2026-05-15	9,728,302	-5.1%	4,914,298	1.98
2026-04-30	10,255,224	-0.2%	1,102,342	9.30
2026-04-15	10,275,369	+4.2%	1,257,012	8.17
2026-03-31	9,857,461	+5.8%	1,483,946	6.64
2026-03-13	9,318,720	-2.6%	1,414,882	6.59
2026-02-27	9,563,527	-14.1%	1,749,529	5.47
2026-02-13	11,128,203	-2.5%	1,492,464	7.46
2026-01-30	11,408,582	-0.3%	2,021,824	5.64
2026-01-15	11,440,395	+13.7%	1,573,325	7.27
2025-12-31	10,065,114	+14.1%	1,559,295	6.45
2025-12-15	8,817,939	+7.7%	1,148,798	7.68
2025-11-28	8,184,722	+7.9%	1,096,653	7.46
2025-11-14	7,586,108	+11.0%	1,994,485	3.80
2025-10-31	6,831,984	-9.4%	2,212,105	3.09
2025-10-15	7,544,331	-5.6%	3,650,630	2.07
2025-09-30	7,992,013	-19.1%	2,170,112	3.68
2025-09-15	9,877,527	+2.3%	1,427,418	6.92
2025-08-29	9,652,874	+2.7%	1,348,615	7.16
2025-08-15	9,401,919	+1.3%	1,544,130	6.09
2025-07-31	9,279,254	-1.9%	1,469,784	6.31
2025-07-15	9,460,646	-0.9%	1,376,072	6.88
2025-06-30	9,544,385	+0.3%	1,791,376	5.33
2025-06-13	9,512,319	-13.9%	2,579,848	3.69
2025-05-30	11,045,558	-14.2%	1,579,140	6.99
2025-05-15	12,870,954	-3.5%	1,887,503	6.82
2025-04-30	13,339,789	-14.4%	2,211,598	6.03
2025-04-15	15,586,689	-4.8%	2,671,472	5.83
2025-03-31	16,374,114	+12.4%	1,259,532	13.00
2025-03-14	14,571,003	+9.3%	2,500,176	5.83
2025-02-28	13,328,335	+2.0%	4,280,432	3.11
2025-02-14	13,060,901	+1.5%	1,439,805	9.07
2025-01-31	12,869,655	+1.4%	1,352,663	9.51
2025-01-15	12,698,496	+13.4%	3,218,727	3.95
2024-12-31	11,195,194	-8.1%	3,559,970	3.14
2024-12-13	12,186,948	+7.4%	3,272,528	3.72
2024-11-29	11,348,453	+9.2%	6,837,206	1.66
2024-11-15	10,388,854	-34.7%	1,618,313	6.42
2024-10-31	15,902,286	-1.0%	1,296,673	12.26

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of FATE volume is 37.7%, down 36.4 points over the last five sessions. Over the last 30 readings it ranged from 32.8% (5 October 2026) to 83.4% (25 September 2026). The latest reading sits at the bottom of that range. The latest reading is 14.8 points below the 30-session average of 52.5%, on 525K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-02	198K	525K	37.7%	9
2026-10-30	228K	379K	60.2%	400
2026-10-29	141K	329K	42.9%	12
2026-10-28	140K	342K	40.8%	186
2026-10-27	206K	396K	52.0%	1,800
2026-10-26	446K	601K	74.1%	0
2026-10-23	267K	423K	63.2%	239
2026-10-22	183K	265K	69.1%	34
2026-10-21	278K	451K	61.7%	1,014
2026-10-20	453K	889K	51.0%	5,408
2026-10-19	310K	562K	55.1%	0
2026-10-16	317K	574K	55.2%	2,116
2026-10-15	206K	388K	53.1%	11
2026-10-14	265K	553K	48.0%	328
2026-10-13	229K	419K	54.6%	6
2026-10-12	86K	219K	39.4%	0
2026-10-09	134K	296K	45.4%	0
2026-10-08	212K	417K	51.0%	5,418
2026-10-07	112K	311K	35.9%	65
2026-10-06	301K	468K	64.3%	861
2026-10-05	360K	1.1M	32.8%	579
2026-10-02	178K	316K	56.2%	316
2026-10-01	155K	301K	51.4%	0
2026-09-30	160K	430K	37.3%	0
2026-09-29	325K	509K	63.7%	456
2026-09-28	296K	488K	60.7%	0
2026-09-25	1.3M	1.5M	83.4%	290
2026-09-24	284K	533K	53.3%	4,305
2026-09-23	133K	344K	38.7%	20
2026-09-22	310K	722K	43.0%	15,579

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 8 October 2026, the fails-to-deliver balance in FATE is 1,977 shares, down 2,030 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (17 July 2026) to 17,848 shares (10 August 2026).

Settlement	Shares failed	Price	Value
2026-10-08	1,977	$2.15	$4K
2026-10-01	4,007	$2.37	$9K
2026-09-30	400	$2.38	$952
2026-09-29	99	$2.38	$236
2026-09-28	4,000	$2.35	$9K
2026-09-22	270	$2.53	$683
2026-09-21	1,553	$2.53	$4K
2026-09-09	6,075	$2.50	$15K
2026-09-04	368	$2.42	$891
2026-09-03	370	$2.45	$907
2026-09-02	39	$2.43	$95
2026-08-31	26	$2.43	$63
2026-08-25	6,625	$2.44	$16K
2026-08-20	1,022	$2.65	$3K
2026-08-10	17,848	$2.80	$50K
2026-08-04	451	$2.50	$1K
2026-07-27	2	$2.41	$5
2026-07-17	1	$2.73	$3
2026-07-16	647	$2.99	$2K
2026-07-14	4,438	$3.02	$13K
2026-07-13	5,238	$3.10	$16K
2026-07-01	9,768	$2.70	$26K
2026-06-26	1,597	$1.87	$3K
2026-06-22	5,144	$2.09	$11K
2026-06-16	290	$2.01	$583
2026-06-15	2,372	$2.06	$5K
2026-06-12	7,947	$1.97	$16K
2026-06-10	1,265	$1.90	$2K
2026-06-03	17,792	$2.57	$46K
2026-06-02	3,046	$2.74	$8K

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for FATE in the last 90 days. The most recent filings are listed below. Latest filing: TAHL CINDY (See Remarks) on 2026-08-04.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-08-04	TAHL CINDY	See Remarks	Sell	39K	$2.46	$95K	589K
2026-08-04	Valamehr Bahram	President and CEO	Sell	44K	$2.46	$108K	592K
2026-05-20	TAHL CINDY	See Remarks	Sell	26K	$1.88	$48K	628K
2026-05-20	Valamehr Bahram	President and CEO	Sell	29K	$1.88	$54K	636K
2026-05-06	TAHL CINDY	See Remarks	Exercise or conversion	44K	$1.05	$47K	654K
2026-05-06	TAHL CINDY	See Remarks	Exercise or conversion	122K	$1.32	$161K	609K
2026-05-05	RASTETTER WILLIAM H	Director	Exercise or conversion	25K	$1.69	$42K	36K
2026-05-05	EPSTEIN ROBERT S	Director	Exercise or conversion	25K	$1.69	$42K	36K
2026-04-20	Green Jeremy	Director,TenPercentOwner	Other transaction	9.0M	$0.00	$0	12.9M
2026-04-20	Redmile Group, LLC	Director, 10% owner	Other transaction	9.0M	$0.00	$0	0
2026-01-15	TAHL CINDY	See Remarks	Grant	100K	$0.00	$0	487K
2026-01-15	Valamehr Bahram	President and CEO	Grant	335K	$0.00	$0	665K
2026-01-15	Adawi Kamal	Chief Financial Officer	Grant	25K	$0.00	$0	100K
2026-01-09	TAHL CINDY	See Remarks	Sell	11K	$1.06	$11K	387K
2026-01-09	Valamehr Bahram	President and CEO	Sell	5K	$1.07	$6K	330K
2025-10-20	Adawi Kamal	Chief Financial Officer	Grant	75K	$0.00	$0	75K
2025-08-04	TAHL CINDY	See Remarks	Sell	9K	$1.06	$10K	398K
2025-08-04	Valamehr Bahram	President and CEO	Sell	14K	$1.06	$15K	335K
2025-01-15	Bressi Jerome Charles	See Remarks	Grant	65K	$0.00	$0	335K
2025-01-15	TAHL CINDY	See Remarks	Grant	70K	$0.00	$0	407K
2025-01-10	Valamehr Bahram	President and CEO	Sell	9K	$1.54	$13K	349K
2025-01-10	TAHL CINDY	See Remarks	Sell	6K	$1.55	$9K	337K
2025-01-10	Bressi Jerome Charles	See Remarks	Sell	6K	$1.55	$9K	270K
2024-12-20	Green Jeremy	Director,TenPercentOwner	Buy	398K	$1.68	$669K	12.9M
2024-12-20	Green Jeremy	Director,TenPercentOwner	Other transaction	1.1M	$1.68	$1.8M	12.8M
2024-12-20	Green Jeremy	Director,TenPercentOwner	Sell	342K	$1.68	$574K	12.5M
2024-12-12	Green Jeremy	Director,TenPercentOwner	Conversion	30K	price not stated in the filing	not stated	12.8M
2024-08-06	Xu Yuan	Director	Sell	633	$4.23	$3K	9K
2024-07-29	TAHL CINDY	General Counsel and Secretary	Grant	200K	$0.00	$0	342K
2024-07-29	Valamehr Bahram	Chief R&D Officer	Grant	200K	$0.00	$0	358K
2024-03-04	Dulac Edward J III	Chief Financial Officer	Sell	2K	$7.77	$19K	101K
2024-01-29	Dulac Edward J III	Chief Financial Officer	Sell	2K	$5.00	$9K	104K
2024-01-09	Dulac Edward J III	Chief Financial Officer	Sell	7K	$4.37	$31K	106K
2024-01-09	Wolchko J Scott	President and CEO	Sell	14K	$4.37	$63K	371K
2024-01-09	Valamehr Bahram	Chief R&D Officer	Sell	11K	$4.38	$49K	158K
2024-01-09	TAHL CINDY	General Counsel and Secretary	Sell	11K	$4.37	$48K	142K
2024-01-02	Dulac Edward J III	Chief Financial Officer	Sell	5K	$3.66	$19K	113K
2023-12-26	Redmile Group, LLC	Director, 10% owner	Other transaction	1.7M	$3.72	$6.2M	13.1M
2023-12-26	Redmile Group, LLC	Director,TenPercentOwner	Other transaction	1.7M	$3.72	$6.2M	13.1M
2023-12-26	Redmile Group, LLC	Director,TenPercentOwner	Buy	45K	$3.72	$166K	13.2M
2023-12-18	Dulac Edward J III	Chief Financial Officer	Sell	2K	$3.50	$6K	118K
2023-11-09	TAHL CINDY	General Counsel and Secretary	Sell	24K	$2.40	$58K	153K
2023-08-18	Dulac Edward J III	Chief Financial Officer	Sell	5K	$2.80	$13K	120K
2023-08-04	Xu Yuan	Director	Sell	632	$3.71	$2K	9K
2023-07-05	Dulac Edward J III	Chief Financial Officer	Sell	5K	$4.83	$25K	124K
2023-07-05	Powl Brian T.	Chief Commercial Officer	Sell	4K	$4.87	$19K	41K
2023-06-14	Xu Yuan	Director	Sell	3K	$5.58	$19K	10K
2023-04-21	Green Jeremy	Director,TenPercentOwner	Buy	257K	$6.18	$1.6M	13.1M
2023-04-20	Green Jeremy	Director,TenPercentOwner	Buy	20K	$5.99	$120K	12.9M
2023-04-18	Chu Yu-Waye	Chief Medical Officer	Sell	2K	$6.58	$15K	141K
2023-04-18	Chu Yu-Waye	Chief Medical Officer	Sell	215	$6.52	$1K	143K
2023-04-14	Green Jeremy	Director,TenPercentOwner	Sell	302K	$5.84	$1.8M	12.8M
2023-04-14	Green Jeremy	Director,TenPercentOwner	Buy	26K	$6.00	$154K	12.9M
2023-04-14	Green Jeremy	Director,TenPercentOwner	Other transaction	5.5M	$5.84	$32.1M	12.8M
2023-04-13	Green Jeremy	Director,TenPercentOwner	Conversion	167K	price not stated in the filing	not stated	13.1M
2023-01-19	MENDLEIN JOHN	Director	Exercise or conversion	28K	$1.37	$39K	311K
2023-01-13	MENDLEIN JOHN	Director	Buy	37K	$5.43	$199K	283K
2023-01-12	Valamehr Bahram	Chief R&D Officer	Exercise or conversion	423	$1.37	$580	169K
2023-01-11	MENDLEIN JOHN	Director	Buy	88K	$5.67	$499K	246K
2023-01-10	Chu Yu-Waye	Chief Medical Officer	Sell	8K	$5.24	$41K	143K
2023-01-10	Dulac Edward J III	Chief Financial Officer	Sell	7K	$5.24	$38K	129K
2023-01-10	Plavsic Mark	Chief Technical Officer	Sell	3K	$5.24	$18K	124K
2023-01-10	TAHL CINDY	General Counsel and Secretary	Sell	12K	$5.24	$61K	178K
2023-01-10	Valamehr Bahram	Chief R&D Officer	Sell	11K	$5.24	$57K	169K
2023-01-10	Wolchko J Scott	President and CEO	Sell	46K	$5.24	$241K	386K
2022-08-18	Dulac Edward J III	Chief Financial Officer	Sell	5K	$29.75	$140K	137K
2022-08-18	Dulac Edward J III	Chief Financial Officer	Sell	432	$30.41	$13K	137K
2022-07-22	Wolchko J Scott	President and CEO	Exercise or conversion	6K	$2.70	$17K	438K
2022-07-22	Wolchko J Scott	President and CEO	Sell	3K	$31.33	$92K	435K
2022-07-22	Wolchko J Scott	President and CEO	Sell	620	$33.28	$21K	432K
2022-07-22	Wolchko J Scott	President and CEO	Sell	3K	$32.61	$88K	432K
2022-07-21	Wolchko J Scott	President and CEO	Sell	11K	$32.54	$352K	451K
2022-07-21	Wolchko J Scott	President and CEO	Sell	19K	$33.07	$634K	432K
2022-07-21	Wolchko J Scott	President and CEO	Exercise or conversion	30K	$2.70	$81K	462K
2022-07-07	Valamehr Bahram	Chief R&D Officer	Exercise or conversion	17K	$2.73	$47K	197K
2022-07-07	Valamehr Bahram	Chief R&D Officer	Sell	17K	$30.23	$519K	180K
2022-07-06	Valamehr Bahram	Chief R&D Officer	Exercise or conversion	6K	$2.73	$16K	188K
2022-07-06	Valamehr Bahram	Chief R&D Officer	Exercise or conversion	2K	$4.84	$10K	182K
2022-07-06	Valamehr Bahram	Chief R&D Officer	Sell	8K	$30.07	$236K	180K
2022-07-05	Plavsic Mark	Chief Technical Officer	Sell	4K	$24.61	$92K	127K
2022-06-27	Powl Brian T.	Chief Commercial Officer	Grant	45K	$0.00	$0	45K
2022-06-09	Agarwal Shefali	Director	Grant	9K	$0.00	$0	10K
2022-06-09	COUGHLIN TIMOTHY	Director	Grant	9K	$0.00	$0	10K
2022-06-09	EPSTEIN ROBERT S	Director	Grant	9K	$0.00	$0	11K
2022-06-09	HERSHBERG ROBERT	Director	Grant	9K	$0.00	$0	11K
2022-06-09	Jooss Karin	Director	Grant	9K	$0.00	$0	10K
2022-06-09	MENDLEIN JOHN	Director	Grant	9K	$0.00	$0	167K
2022-06-09	RASTETTER WILLIAM H	Director	Grant	9K	$0.00	$0	11K
2022-06-09	Xu Yuan	Director	Grant	9K	$0.00	$0	13K
2022-06-09	Lee Michael Stewart	Director	Grant	9K	$0.00	$0	11K
2022-06-09	Redmile Group, LLC	Director,TenPercentOwner	Grant	9K	$0.00	$0	13.0M
2022-06-07	Agarwal Shefali	Director	Sell	841	$21.89	$18K	2K
2022-06-03	Agarwal Shefali	Director	Sell	807	$22.80	$18K	2K
2022-06-03	COUGHLIN TIMOTHY	Director	Sell	1K	$22.81	$33K	58K
2022-06-03	HERSHBERG ROBERT	Director	Sell	672	$22.75	$15K	2K
2022-06-03	Jooss Karin	Director	Sell	1K	$22.82	$34K	1K
2022-06-03	MENDLEIN JOHN	Director	Sell	1K	$22.79	$31K	158K
2022-06-03	Agarwal Shefali	Director	Sell	0	$0.00	$0	3K
2022-06-01	TAHL CINDY	General Counsel and Secretary	Exercise or conversion	25K	$6.55	$164K	214K
2022-06-01	TAHL CINDY	General Counsel and Secretary	Sell	25K	$22.96	$574K	189K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

7 Form 144 notices on file for FATE worth $362K at the prices reported; 0 in the last 90 days worth $0. Latest: TAHL CINDY filed on 2026-08-04 to sell 38,800 shares ($95K) from 2026-08-04.

Filed	Seller	Shares	Market value	Of outstanding	Sale from	Broker
2026-08-04	TAHL CINDYOfficer	39K	$95K	0.033%	2026-08-04	Fidelity Brokerage Services LLC
2026-08-04	Valamehr BahramOfficer, Director	44K	$108K	0.038%	2026-08-04	Fidelity Brokerage Services LLC
2026-05-20	Valamehr BahramOfficer, Director	29K	$54K	0.025%	2026-05-20	Fidelity Brokerage Services LLC
2026-05-20	TAHL CINDYOfficer	26K	$48K	0.022%	2026-05-20	Fidelity Brokerage Services LLC
2026-01-09	TAHL CINDYOfficer	11K	$11K	0.009%	2026-01-09	Fidelity Brokerage Services LLC
2026-01-09	Valamehr BahramOfficer, Director	5K	$6K	0.004%	2026-01-09	Fidelity Brokerage Services LLC
2025-12-29	MENDLEIN JOHNFormer Director	38K	$39K	0.033%	2025-12-24	Fidelity Brokerage Services LLC

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

3 holders report 5% or more of FATE in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Redmile Group, LLC at 14.9% of the class (18,229,078 shares), filed 2026-04-22 for an event on 2026-04-20.

Filed	Form	Holder	Shares	Of class	Event
2026-07-08	13G/Ano. 8	BlackRock, Inc.parent holding company	2.2M	1.9%	2026-06-30
2026-04-22	13D/Ano. 10	Redmile Group, LLCinvestment adviser, other entity	18.2M	14.9%	2026-04-20
2026-04-22	13D/Ano. 10	Jeremy C. Greenindividual, parent holding company	18.2M	14.9%	2026-04-20
2026-04-22	13D/Ano. 10	RedCo II Offshore SPV LLCother entity	10.1M	8.5%	2026-04-20
2026-04-22	13D/Ano. 10	RedCo II Master Fund, L.P.partnership	0	0.0%	2026-04-20
2026-03-26	13G/Ano. 6	The Vanguard Groupinvestment adviser	0	0.0%	2026-03-13

13F holders

Tracked managers holding FATE at their latest 13F. JSON

6 of the 30 tracked managers held FATE at their latest 13F, $38.6M in total at quarter-end prices. AQR Capital Management is the largest at $10.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 0 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
AQR Capital Management	2026-06-30	3.8M	$10.4M	0.00%	+836K
Two Sigma Investments	2026-06-30	3.6M	$9.7M	0.01%	+123K
Renaissance Technologies	2026-06-30	3.0M	$8.1M	0.01%	+9K
Millennium Management	2026-06-30	2.4M	$6.6M	0.00%	new
Citadel Advisors	2026-06-30	993K	$2.7M	0.00%	+50K
Point72 Asset Management	2026-06-30	442K	$1.2M	0.00%	+399K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

Fate Therapeutics in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Fate Therapeutics (FATE), SEC CIK 1434316, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-08.JSON and CSV
Planned sales: SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-04.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-08.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-04.JSON and CSV
Company record: EDGAR filing index for CIK 1434316Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as biological products, (no diagnostic substances)

Other company pages

Datasets

Frequently Asked Questions

How much of FATE is sold short?

10,618,410 shares were held short at the 2026-10-15 settlement, 8.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is FATE's daily short volume?

On 2026-11-02, 197,929 of the 525,047 FATE shares reported to FINRA were sold short, 37.7% of the day's reported volume. Short volume is a flow for one day, not a position.

Does FATE have fails to deliver?

The SEC's latest file shows 1,977 FATE shares failed to deliver at settlement 2026-10-08. Fails are reported per settlement date and published twice a month with a lag.

Are FATE insiders buying or selling?

No open-market insider trades were reported for FATE in the last 90 days. The most recent filings are listed below. Latest filing: TAHL CINDY (See Remarks) on 2026-08-04.

Have FATE insiders filed to sell?

7 Form 144 notices on file for FATE worth $362K at the prices reported; 0 in the last 90 days worth $0. Latest: TAHL CINDY filed on 2026-08-04 to sell 38,800 shares ($95K) from 2026-08-04.

Who owns 5% or more of FATE?

Which tracked 13F managers own FATE?

6 of the 30 tracked 13F managers held FATE shares at their latest filing, $38.6M in all. The largest: Cliff Asness's AQR Capital Management (3.8M shares, $10.4M), Two Sigma Investments (3.6M shares, $9.7M), Renaissance Technologies (3.0M shares, $8.1M), Izzy Englander's Millennium Management (2.4M shares, $6.6M), Ken Griffin's Citadel Advisors (993K shares, $2.7M), Steve Cohen's Point72 Asset Management (442K shares, $1.2M).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.